Glenmark Pharma gets EIR for Goa facility from US FDA
23 Sept 2026 · Business Standard Mkts
Glenmark Pharmaceuticals said that it has received the establishment inspection report (EIR) from the U.S. Food and Drug Administration (U.S. FDA) for its formulations manufacturing facility in Goa, India.
The analysis
This is an USFDA action event. US regulatory status gates the export revenue that drives most Indian pharma earnings. A clearance reopens filings from that site; an alert freezes them, and the impact lands over quarters rather than days.
Market context
- Sector exposure: Pharma & Healthcare.
In this story
Related coverage
Market wrap: ITC, BSE, HCL Tech, Asian Paints top gainers and losers on Nifty and Sensex on Monday
Stock Market Today LIVE: Sensex Rises 500 Points, Nifty 50 Holds 22,700; India VIX Leaps 7%; Trent Rallies 12%
Last line of defence! How 7 Nifty stocks survived the market’s two-month bloodbath
Divi's Labs, TVS Motor could replace Max Healthcare, HDFC Life in Nifty 2027 index review
Buy, Sell Or Hold: HDFC Bank, Sun Pharma, Rallis India, Trent | Ask Profit